Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Elsevier 2023-08-01
Sraith:Journal of Allergy and Clinical Immunology: Global
Ábhair:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Rochtain ar líne:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Ar líne

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Míreanna comhchosúla